Spectral AI to present DeepView System at BBA Annual Conference
Spectral AI, Inc. is set to participate in the 2026 British Burn Association Annual Meeting in Nottingham, England, from June 17-19, 2026. The company will feature its DeepView System, which recently gained FDA De Novo Classification and UKCA authorization. Spectral AI anticipates launching its first commercial sales of the system by the end of 2026.
*this image is generated using AI for illustrative purposes only.
Spectral AI, Inc. will showcase its DeepView System at the 2026 British Burn Association (BBA) Annual Meeting, scheduled for June 17-19, 2026, at Nottingham Trent University in Nottingham, England. The company, focused on artificial intelligence for medical diagnostics in wound care, will display the technology at Stand #22. The system will be the subject of multiple podium and poster presentations during the multidisciplinary conference, which brings together burn care professionals to share clinical experience and research.
The DeepView System recently received De Novo Classification from the U.S. Food and Drug Administration (FDA) in May 2026. It also obtained initial UKCA (UK Conformity Assessed) authorization in the United Kingdom in February 2024. Spectral AI expects to generate its first commercial sales of the DeepView System by the end of 2026.
Vincent Capone, Chief Executive Officer of Spectral AI, highlighted the significance of the recent FDA approval. He stated that the classification has created significant runway for enhanced long-term shareholder value. The company aims to elevate the profile of its technology among the burn community by sharing data on the efficacy and impact of the DeepView System in burn wound assessment.
DeepView System Specifications
The DeepView System is a non-invasive, predictive medical device that combines multispectral imaging with a proprietary AI algorithm. It assesses the healing potential of areas within burn wounds to inform treatment decisions.
| Feature | Detail |
|---|---|
| Assessment | Identifies areas unlikely to heal within 21 days |
| Image Acquisition Time | 0.2 seconds |
| Processing Time | Approximately 20 to 25 seconds |
| Database Size | Over 340 billion pixels of burn wound image data |
The system provides clinicians with an immediate, data-driven assessment of whether wounds require significant medical intervention. This enables earlier and more informed treatment decisions, with the goal of improving patient outcomes and reducing healthcare costs.
How will the company leverage the recent FDA De Novo classification to accelerate market adoption in the U.S. compared to the UK market?
What specific sales targets or revenue projections has Spectral AI established for the initial commercial rollout by the end of 2026?
Are there plans to expand the DeepView System's applications beyond burn wound assessment into other areas of wound care?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
